Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

KV Settles DoJ Complaint Over Claims For Unapproved Drugs; Two Dozen Companies Sued

This article was originally published in The Pink Sheet Daily

Executive Summary

The $17 million settlement resolves a False Claims Act suit alleging KV’s Ethex subsidiary illegally received reimbursement for two unapproved drugs; at least three other companies have previously settled with the government.

You may also be interested in...



The Era Of Billion Dollar Pharma Settlements

Abbott Laboratories is the third pharmaceutical company to reach a settlement with the Department of Justice in excess of $1 billion. A look at the deals struck since Eli Lilly began the billion dollar club in 2009 shows the activities the government is investigating and the level of liability that companies face.

Forest Admits To Knowingly Obstructing FDA Inspection In Guilty Pleas On Levothroid, Celexa Marketing

Forest Pharmaceuticals reached a $313 million settlement with the Department of Justice to resolve criminal charges of obstructing an FDA inspection and distributing a misbranded drug and civil False Claims Act allegations.

Schwarz Pharma Settles False Claims Suit For $22 Million, As DoJ Continues Focus On DESI Drugs

Lawsuit alleges Schwarz failed to advise CMS that two products, including the nitroglycerin patch Deponit, did not qualify for federal reimbursement.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073130

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel